Company news
Schrodinger, Inc. (NASDAQ:SDGR) news
Schrodinger, Inc. news releases on 6ix. Latest, Sep 9, 2026: Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New…
Press releases & updates
Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
September 9, 2026
Schrodinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
August 6, 2026
Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery
August 5, 2026
Schrödinger Introduces Bunsen, an AI Co-Scientist for Molecular Discovery
July 27, 2026
Schrödinger to Announce Second Quarter 2026 Financial Results on August 5
July 22, 2026
Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 25, 2026
Schrödinger Reports First Quarter 2026 Financial Results
May 5, 2026
Schrödinger to Announce First Quarter 2026 Financial Results on May 5
April 21, 2026
Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results
February 24, 2026
Schrodinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25
February 12, 2026
Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25
February 11, 2026
Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities
January 12, 2026
Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign
January 8, 2026
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
December 16, 2025
Schrödinger to Present at Jefferies London Healthcare Conference
November 5, 2025
Schrödinger Reports Third Quarter 2025 Financial Results
November 4, 2025
Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger
October 30, 2025
Schrödinger to Announce Third Quarter 2025 Financial Results on November 5
October 21, 2025
Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635c4
October 16, 2025
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
August 26, 2025
Schrödinger Announces Discontinuation of SGR-2921 Program
August 13, 2025
Schrödinger Reports Second Quarter 2025 Financial Results
August 6, 2025
Schrödinger to Announce Second Quarter 2025 Financial Results on August 6
July 24, 2025
Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target
July 16, 2025
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia
June 26, 2025
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
June 11, 2025
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
May 28, 2025
Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing
May 28, 2025
Schrödinger to Present at Jefferies Global Healthcare Conference
May 21, 2025
Schrödinger Announces CFO Appointment
May 19, 2025
Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
May 13, 2025
Schrödinger Reports Strong First Quarter 2025 Financial Results
May 6, 2025
Schrödinger to Present at BofA Securities 2025 Healthcare Conference
May 4, 2025
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
April 27, 2025
Schrödinger to Announce First Quarter 2025 Financial Results on May 7
April 22, 2025
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
April 13, 2025
Schrödinger to Present Preclinical Data at AACR Annual Meeting
March 24, 2025
Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen
March 9, 2025
Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results
February 25, 2025
Schrödinger to Participate in Upcoming Investor Conferences
February 23, 2025
Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26
February 11, 2025
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
January 12, 2025
Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference
November 19, 2024
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
November 17, 2024
Schrödinger Reports Third Quarter 2024 Financial Results
November 11, 2024
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
November 11, 2024
Schrödinger to Announce Third Quarter 2024 Financial Results on November 12
October 30, 2024
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
October 22, 2024
Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium
October 8, 2024
Schrödinger Reports Strong Second Quarter 2024 Financial Results
July 30, 2024